Edwards Lifesciences Corp
NYSE:EW
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
59.7
95.56
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Edwards Lifesciences Corp
Edwards Lifesciences Corp
Cash & Cash Equivalents
Edwards Lifesciences Corp
Cash & Cash Equivalents Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash & Cash Equivalents | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Edwards Lifesciences Corp
NYSE:EW
|
Cash & Cash Equivalents
$3.7B
|
CAGR 3-Years
35%
|
CAGR 5-Years
25%
|
CAGR 10-Years
25%
|
|
|
Becton Dickinson and Co
NYSE:BDX
|
Cash & Cash Equivalents
$1.7B
|
CAGR 3-Years
-9%
|
CAGR 5-Years
26%
|
CAGR 10-Years
-1%
|
|
|
Boston Scientific Corp
NYSE:BSX
|
Cash & Cash Equivalents
$2.5B
|
CAGR 3-Years
9%
|
CAGR 5-Years
55%
|
CAGR 10-Years
26%
|
|
|
Stryker Corp
NYSE:SYK
|
Cash & Cash Equivalents
$3.9B
|
CAGR 3-Years
15%
|
CAGR 5-Years
15%
|
CAGR 10-Years
11%
|
|
|
Abbott Laboratories
NYSE:ABT
|
Cash & Cash Equivalents
$7B
|
CAGR 3-Years
-9%
|
CAGR 5-Years
11%
|
CAGR 10-Years
7%
|
|
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
Cash & Cash Equivalents
$2.4B
|
CAGR 3-Years
21%
|
CAGR 5-Years
20%
|
CAGR 10-Years
17%
|
|
Edwards Lifesciences Corp
Glance View
Edwards Lifesciences Corp., a leader in heart valve technologies and hemodynamic monitoring, has carved out a vital niche in the medical device industry. Founded in 1958 and based in Irvine, California, the company has consistently focused on innovative solutions to treat advanced cardiovascular diseases. Its flagship product, the transcatheter aortic valve replacement (TAVR), revolutionized how patients with severe aortic stenosis are treated, allowing doctors to perform minimally invasive procedures that significantly improve patient outcomes. As the global population ages and cardiovascular diseases become increasingly prevalent, Edwards is well-positioned to capitalize on this growing demand, with a robust pipeline of products aimed at addressing unmet medical needs. For investors, Edwards Lifesciences represents a compelling opportunity to tap into the expanding medical technology market. The company's strong financial performance, characterized by consistent revenue growth and impressive profit margins, highlights its effective execution and market leadership. Moreover, Edwards is committed to innovation, investing heavily in research and development, which not only fuels new product launches but also enhances its competitive edge. With a focus on long-term growth, expanding market presence, and a dedication to improving patient care, Edwards Lifesciences stands out as a promising investment for those looking to gain exposure to the dynamic healthcare sector.
See Also
What is Edwards Lifesciences Corp's Cash & Cash Equivalents?
Cash & Cash Equivalents
3.7B
USD
Based on the financial report for Sep 30, 2024, Edwards Lifesciences Corp's Cash & Cash Equivalents amounts to 3.7B USD.
What is Edwards Lifesciences Corp's Cash & Cash Equivalents growth rate?
Cash & Cash Equivalents CAGR 10Y
25%
Over the last year, the Cash & Cash Equivalents growth was 161%. The average annual Cash & Cash Equivalents growth rates for Edwards Lifesciences Corp have been 35% over the past three years , 25% over the past five years , and 25% over the past ten years .
You don't have any saved screeners yet
